Difference between revisions of "Part:BBa K4387995:Design"

 
 
(One intermediate revision by the same user not shown)
Line 7: Line 7:
  
 
===Design Notes===
 
===Design Notes===
−
The humanized amino acid sequence was converted into DNA sequence using ... and then codon optimized for E. coli with the help of the codon optimization tool provided by Integrated DNA Technologies (IDT).
+
The amino acid sequence was converted into DNA and then codon optimized for E. coli with the help of the codon optimization tool provided by Integrated DNA Technologies (IDT).
−
 
+
  
  
 
===Source===
 
===Source===
 +
The amino acid sequence was directly taken from the patent mentioned in the description. [1]
  
−
The amino acid sequence was directly taken from the patent mentioned in the description. [3]
 
  
 
===References===
 
===References===
 +
* [1] Silence, Karen, Lauwereys, Marc, De Haard, Hans, et al. "Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor", Int. Publication Number: WO 2004/041862 A2, 21 May 2004

Latest revision as of 15:46, 8 October 2022


Monovalent Anti-Tumour Necrosis Factor Nanobody (VHH#3E)


Assembly Compatibility:
  • 10
    COMPATIBLE WITH RFC[10]
  • 12
    COMPATIBLE WITH RFC[12]
  • 21
    COMPATIBLE WITH RFC[21]
  • 23
    COMPATIBLE WITH RFC[23]
  • 25
    COMPATIBLE WITH RFC[25]
  • 1000
    COMPATIBLE WITH RFC[1000]


Design Notes

The amino acid sequence was converted into DNA and then codon optimized for E. coli with the help of the codon optimization tool provided by Integrated DNA Technologies (IDT).


Source

The amino acid sequence was directly taken from the patent mentioned in the description. [1]


References

  • [1] Silence, Karen, Lauwereys, Marc, De Haard, Hans, et al. "Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor", Int. Publication Number: WO 2004/041862 A2, 21 May 2004